Patient’s Stroke Caused by Xarelto. A lawsuit filed against Bayer and Johnson & Johnson unit, Janssen Pharmaceuticals, alleges that its anticoagulant drug Xarelto is to blame for a patient’s stroke.
Unlike the other cases pending in the litigation, this lasuit takes issue with the dosage of the drug. The plaintiff alleges that the once-daily dosage, which fails to take the weight or size of the patient into account, was ineffective at preventing his stroke.
Other Xarelto lawsuits focus on uncontrollable bleeding injuries, and the lack of an antidote for hemorrhages.
The lawsuit was filed in October 2015. The plaintiff began taking Xarelto to prevent blood clots and stroke due to his atrial fibrillation. He alleges the dosage failed to protect him from a stroke.
The U.S. Food and Drug Administration (FDA) approved Xarelto in 2011 to prevent blood clots
The U.S. Food and Drug Administration (FDA) approved Xarelto in 2011 to prevent blood clots and stroke in high-risk patients such as those with deep vein thrombosis, and those recovering from procedures such as hip and knee replacements.
Plaintiffs in the Xarelto litigation highlight the fact that there is no antidote to reverse bleeding if it occurs. This is not the case with warfarin, an older anticoagulant. Plaintiffs allege that Xarelto was marketed as superior to warfarin due to lack of blood testing and dietary restrictions, but drug makers failed to warn that it can lead to potentially fatal bleeding.
Thousands of lawsuits have been filed over Xarelto, including 550 in the Philadelphia Court of Common Pleas. A multidistrict litigation (MDL) has been consolidated in Eastern Louisiana, and more than 2,800 cases have been consolidated.